Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity
Pharmaceuticals · 07.10.2025 · 18 (10) · 1502
DOI: 10.3390/ph18101502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 07.10.2025. Verfasst von Dmytro Khylyuk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Chair and Department of Organic Chemistry, Medical University of Lublin, ul. Chodźki 4a, 20-093 Lublin, Poland. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin, National Research Foundation of Ukraine.
Abstract (Originalsprache)
Background
Cancer remains a leading cause of morbidity and mortality worldwide, and current therapies are limited by toxicity, cost, and resistance. Inhibition of the MDM2–p53 interaction is a promising anticancer strategy, as this pathway is frequently dysregulated across tumors. Spiro-isatin-thiazolidinone derivatives have shown diverse biological activities, including anticancer effects, but require optimization to improve potency and selectivity. The aims were to design, synthesize, and evaluate novel spiro-isatin-thiazolidinone hybrids with enhanced cytotoxicity against cancer cells and reduced toxicity toward normal cells.
Methods
Derivatives were designed using molecular docking against MDM2, followed by structural optimization. Cytotoxic activity was evaluated in vitro by MTT assays on human and murine cancer cell lines and pseudo-normal cells. Docking and 100 ns molecular dynamics simulations assessed binding stability, while ADMET properties were predicted in silico.
Results
Several derivatives exhibited micromolar cytotoxicity, with compound 18 emerging as the most potent and selective candidate (IC50 6.67–8.37 µM across most cancer lines; >100 µM in HaCaT). Docking showed a strong affinity for MDM2 (−10.16 kcal/mol), comparable to the reference ligand, and stable interactions in simulations. ADMET predictions confirmed good oral bioavailability and moderate acute toxicity, fully compliant with Lipinski’s Rule of Five. Overall, the newly synthesized spiro-isatin-thiazolidinone hybrids, particularly compound 18, demonstrated potent and selective anticancer activity, favorable pharmacokinetic properties and a good toxicity profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chair and Department of Organic Chemistry, Medical University of Lublin, ul. Chodźki 4a, 20-093 Lublin, Poland.
- Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, 69 Pekarska St., 79010 Lviv, Ukraine.
- Department of Organic and Pharmaceutical Chemistry, Lesya Ukrainka Volyn National University, 13 Volya Ave., 43025 Lutsk, Ukraine.
- Institute of Cell Biology of National Academy of Sciences of Ukraine, 14/16 Drahomanov Str., 79005 Lviv, Ukraine.
- Department of Microbiology, Danylo Halytsky Lviv National Medical University, 69 Pekarska St., 79010 Lviv, Ukraine.
- Department of Biotechnology and Cell Biology, Medical College, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225 Rzeszow, Poland.
ORCID-Profile: Dmytro Khylyuk, Serhii Holota, Natalia Finiuk, Rostyslav Stoika, Tetyana Rumynska, Roman Lesyk
Förderung
- Medical University of Lublin
- National Research Foundation of Ukraine
Zitieren
APA
Khylyuk, D., Holota, S., Finiuk, N., Stoika, R., Rumynska, T., & Lesyk, R. (2025). Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity. Pharmaceuticals, 18(10), 1502. https://doi.org/10.3390/ph18101502
Vancouver
Khylyuk D, Holota S, Finiuk N, Stoika R, Rumynska T, Lesyk R. Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity. Pharmaceuticals. 2025;18(10):1502. doi:10.3390/ph18101502
BibTeX
@article{Khylyuk2025,
author = {Khylyuk, Dmytro and Holota, Serhii and Finiuk, Natalia and Stoika, Rostyslav and Rumynska, Tetyana and Lesyk, Roman},
title = {Design and Optimization of Spiro-Isatin-Thiazolidinone Hybrids with Promising Anticancer Activity},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {10},
pages = {1502},
doi = {10.3390/ph18101502}
}
EUVIMED